Compare VCEL & BUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCEL | BUR |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | Guernsey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.0B |
| IPO Year | 1996 | 2017 |
| Metric | VCEL | BUR |
|---|---|---|
| Price | $35.06 | $4.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $57.75 | $13.58 |
| AVG Volume (30 Days) | 702.1K | ★ 6.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.64% |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ 0.32 | 0.28 |
| Revenue | $276,259,000.00 | ★ $413,360,000.00 |
| Revenue This Year | $19.10 | $73.90 |
| Revenue Next Year | $17.95 | $5.52 |
| P/E Ratio | $110.64 | ★ $16.93 |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $28.95 | $3.59 |
| 52 Week High | $45.97 | $14.61 |
| Indicator | VCEL | BUR |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 33.19 |
| Support Level | $34.26 | $3.59 |
| Resistance Level | $38.48 | $4.90 |
| Average True Range (ATR) | 1.37 | 0.59 |
| MACD | 0.46 | 0.06 |
| Stochastic Oscillator | 94.67 | 27.07 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.